These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review. Mavrakanas TA; Gariani K; Martin PY Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413 [TBL] [Abstract][Full Text] [Related]
9. The renoprotective effect of esaxerenone independent of blood pressure lowering: a post hoc mediation analysis of the ESAX-DN trial. Okuda Y; Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Sawanobori T; Taguri M Hypertens Res; 2023 Feb; 46(2):437-444. PubMed ID: 36100672 [TBL] [Abstract][Full Text] [Related]
10. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. Zou H; Zhou B; Xu G Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711 [TBL] [Abstract][Full Text] [Related]
11. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats. Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458 [TBL] [Abstract][Full Text] [Related]
12. The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy. Goenka L; Padmanaban R; George M Curr Clin Pharmacol; 2019; 14(2):78-83. PubMed ID: 30444201 [TBL] [Abstract][Full Text] [Related]
14. Angiotensin II receptor blocker inhibits p27Kip1 expression in glucose-stimulated podocytes and in diabetic glomeruli. Xu ZG; Yoo TH; Ryu DR; Cheon Park H; Ha SK; Han DS; Adler SG; Natarajan R; Kang SW Kidney Int; 2005 Mar; 67(3):944-52. PubMed ID: 15698433 [TBL] [Abstract][Full Text] [Related]
15. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311 [TBL] [Abstract][Full Text] [Related]
16. Effect of combining ACE inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis. Kramer AB; van der Meulen EF; Hamming I; van Goor H; Navis G Kidney Int; 2007 Mar; 71(5):417-24. PubMed ID: 17213874 [TBL] [Abstract][Full Text] [Related]
17. Meta-analysis: the efficacy and safety of combined treatment with ARB and ACEI on diabetic nephropathy. Ren F; Tang L; Cai Y; Yuan X; Huang W; Luo L; Zhou J; Zheng Y Ren Fail; 2015 May; 37(4):548-61. PubMed ID: 25707526 [TBL] [Abstract][Full Text] [Related]
18. Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis. Mathew R; Futterweit S; Valderrama E; Tarectecan AA; Bylander JE; Bond JS; Trachtman H Am J Physiol Renal Physiol; 2005 Oct; 289(4):F911-21. PubMed ID: 15942051 [TBL] [Abstract][Full Text] [Related]
19. Impaired angiotensin II AT(1) receptor function and enhanced Na, K-ATPase affinity for sodium in proximal tubule of streptozotocin-treated diabetic rats. Siddiqui AH; Hussain T Clin Exp Hypertens; 2007 Oct; 29(7):435-44. PubMed ID: 17994353 [TBL] [Abstract][Full Text] [Related]
20. Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes. Dong D; Fan TT; Ji YS; Yu JY; Wu S; Zhang L Int Urol Nephrol; 2019 Apr; 51(4):755-764. PubMed ID: 30734886 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]